Dataset Information

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

ABSTRACT: Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive forms of MS.Adipokine levels were measured in untreated adult relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and Healthy control (HC). Pediatric-onset MS (POMS) and pediatric healthy controls (PHC) were also assessed. Leptin and A-FABP levels were measured in serum by ELISA. Groups were compared using linear mixed-effects model.Excluding two patients with Body Mass Index (BMI)?>?50, a significant difference in leptin level was found between RRMS and HC controlling for age (p?=?0.007), SPMS and HC controlling for age alone (p?=?0.002), or age and BMI (p?=?0.007). A-FABP levels were higher in SPMS than HC (p?=?0.007), controlling for age and BMI. Differences in A-FABP levels between POMS and PHC was observed after controlling for age (p?=?0.019), but not when BMI was added to the model (p?=?0.081).Leptin and A-FABP levels are highest in SPMS compared to HC, suggesting a role in pathogenesis of this disease subtype. A-FABP levels are increased in POMS patients and may play a role in the early stages of disease.

SUBMITTER: Messina S

PROVIDER: S-EPMC3829106 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

Messina Silvia S Vargas-Lowy David D Musallam Alexander A Healy Brian C BC Kivisakk Pia P Gandhi Roopali R Bove Riley R Gholipour Taha T Khoury Samia S Weiner Howard L HL Chitnis Tanuja T

BMC neurology 20131111

<h4>Background</h4>Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive forms of MS.<h4>Methods</h4>Adipokine levels were measured in untreated adult relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and Healthy control (HC). Pediatric-onset MS (POMS) and pediatric healthy controls (PH ...[more]

PMID: 24215402

Similar Datasets

Project description:One of our new major finding among the genes that contributes to MS susceptibility is ICSBP1. The so called disease modifying therapies like interferon-beta (IFN-β), possibly acting on the peripheral T-cells, reduce the disease activity and the clinical progression, with a MRI-detectable effect in preventing lesion burden and cerebral atrophy development in RR-MS. It suggests a critical role of peripheral blood mononuclear cells (PBMCs) immune response and modulation in developing inflammation in the brain. We tested the hypothesis that the genetic effect of the susceptible allele ICSBP1 can impact the gene expression profile of molecules belonging to the interferon pathway. We therefore interrogated the PBMC for changes in gene expression profile. We correlate those changes with the minor allele frequency for ICSBP1, performing independent quantitative trait analysis for each treatment category. Expression Quantitative Trait Loci Association with a p value < 0.05 have been used in follow up analysis. The regression coefficient of the Quantitative trait association represents the degree of correlation between the gene expression for each interrogated target gene and the minor allele frequency of the SNP for our gene of interest. This coefficient has been used as input in the subsequent Gene Set Enrichment Analysis performed in a pre-ranked approach. The resulting GSEA-SNP method rests on the assumption that SNPs underlying a disease phenotype might affect genes constituting a signaling pathway or genes with a common regulation. Therefore, GSEA-SNP can facilitate the identification of pathways or of underlying biological mechanisms. We used microarrays to capture gene expression profile of untreated subjects and of subjects under disease modyfing treatment (Interferon Beta and Glatiramer Acetate), in order to correlate gene expression and genotype data and in order to identify sets of genes specifically regulated in the different treatment categories.

Dataset Information

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

Publications

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets